Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pseudomyxoma Peritonei × Sirolimus × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 20 Leukemia, Myeloid, Acute 19 Myelodysplastic Syndromes 18 Lymphoma, Non-Hodgkin 16 Hodgkin Disease 15 Leukemia, Lymphocytic, Chronic, B-Cell 14 Graft vs Host Disease 12 Lymphoma, Mantle-Cell 11 Leukemia 11 Sarcoma 10 Multiple Myeloma 10 Lymphoma, Large B-Cell, Diffuse 10 Lymphoma 9 Burkitt Lymphoma 9 Myeloproliferative Disorders 8 Lymphoma, Follicular 8 Lymphoma, B-Cell, Marginal Zone 8 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7 Hematologic Neoplasms 7 Congenital Abnormalities 7 Waldenstrom Macroglobulinemia 6 Tuberous Sclerosis 6 Primary Myelofibrosis 6 Lymphoma, Large-Cell, Immunoblastic 6 Leukemia, Myelomonocytic, Chronic 6 Leukemia, Myeloid, Chronic-Phase 6 Leukemia, Myeloid, Accelerated Phase 6 Breast Neoplasms 6 Osteosarcoma 5 Neoplasms 5

Interventions

Mitomycin 2 Capecitabine 2 Tacrolimus 1 Specimen Handling 1 Sirolimus 1 Nivolumab 1 Magnetic Resonance Spectroscopy 1 Lansoprazole 1 Ipilimumab 1 Hyperthermic Intraperitoneal Chemotherapy 1 Cytoreduction Surgical Procedures 1 Clarithromycin 1 CTLA-4 Antigen 1 Bromelains 1 Amoxicillin 1 Alemtuzumab 1 Acetylcysteine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06084780 2026-01-23

TRANSCAPE

Case Comprehensive Cancer Center

Phase 2 Not yet recruiting

Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon ⚡